MDM2 and hepatocellular carcinoma: The meta-analysis presented in this study aims to assess whether TP53 R72P and MDM2 SNP309 polymorphisms associated with HCC risk and to investigate the possible combined effect between the MDM2 SNP309 and the TP53 R72P polymorphisms on HCC risk.